Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antofloxacin
- Development stage
- Phase 1
- Lead developer
- Shanghai Institute of Materia Medica
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Antofloxacin is a synthetic broad-spectrum antibacterial agent of the fluoroquinolone class. It acts primarily by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and transcription. Developed as a new molecular entity in China, it is used to treat infections such as acute exacerbation of chronic bronchitis and acute pyelonephritis[2][3][5][7]. Its mechanism of action is similar to other fluoroquinolones but with distinct pharmacokinetic properties.
- Brand names
- none found
- Other names
- antofloxacin hydrochloride(S)-antofloxacin hydrochloride119354-43-7UNII-56A192VX1QUNII56A192VX1QUNII 56A192VX1Q
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on antofloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antofloxacin.